Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.

导出 OA

翻译打印收藏纠错

作者： Jitka,Fucikova ^[1] ; Michal,Podrazil ^[2] ; Ladislav,Jarolim ^[1] ; Pavla,Bilkova ^[3] ; Michal,Hensler ^[2] ; Etienne,Becht ^[2] ; Zdenka,Gasova ^[4] ; Jana,Klouckova ^[5] ; Jana,Kayserova ^[6] ; Rudolf,Horvath ^[7] ; Anna,Fialova ^[8] ; Katerina,Vavrova ^[1] ; Klara,Sochorova ^[1] ; Daniela,Rozkova ^[9] ; Radek,Spisek ^[2] ; Jirina,Bartunkova ^[1]

作者单位： Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic. ^[1] Sotio, Prague, Czech Republic. ^[2] Department of Urology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. ^[3] Laboratory 'Cancer, Immune Control and Escape', INSERM U1138, Cordeliers Research Centre, Paris, France. ^[4] UMRS 1138, University Pierre and Marie Curie, Paris, France. ^[5] UMRS 1138, University Paris Descartes, Paris, France. ^[6] Institute of Hematology and Blood Transfusion, Prague, Czech Republic. ^[7] Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. ^[8] Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic. ^[9] Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic. jirina.bartunkova@lfmotol.cuni.cz. ^[10] Sotio, Prague, Czech Republic. jirina.bartunkova@lfmotol.cuni.cz. ^[11]

关键词 Biochemically recurrent prostate cancer Dendritic cell Immunotherapy PSA doubling time